- Home
- KULR vs MAIA Comparison
KULR vs MAIA Comparison
Compare KULR & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- MAIA
- Stock Information
- Founded
- KULR 2013
- MAIA 2018
- Country
- KULR United States
- MAIA United States
- Employees
- KULR N/A
- MAIA N/A
- Industry
- KULR Electrical Products
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- KULR Technology
- MAIA Health Care
- Exchange
- KULR Nasdaq
- MAIA Nasdaq
- Market Cap
- KULR 55.3M
- MAIA 52.8M
- IPO Year
- KULR N/A
- MAIA 2022
- Fundamental
- Price
- KULR $2.28
- MAIA $2.00
- Analyst Decision
- KULR Strong Buy
- MAIA
- Analyst Count
- KULR 1
- MAIA 0
- Target Price
- KULR $5.00
- MAIA N/A
- AVG Volume (30 Days)
- KULR 53.2M
- MAIA 346.7K
- Earning Date
- KULR 11-13-2024
- MAIA 11-12-2024
- Dividend Yield
- KULR N/A
- MAIA N/A
- EPS Growth
- KULR N/A
- MAIA N/A
- EPS
- KULR N/A
- MAIA N/A
- Revenue
- KULR $9,700,738.00
- MAIA N/A
- Revenue This Year
- KULR $3.70
- MAIA N/A
- Revenue Next Year
- KULR $76.20
- MAIA N/A
- P/E Ratio
- KULR N/A
- MAIA N/A
- Revenue Growth
- KULR 4.20
- MAIA N/A
- 52 Week Low
- KULR $0.10
- MAIA $1.17
- 52 Week High
- KULR $5.49
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- KULR 47.59
- MAIA 44.72
- Support Level
- KULR $2.24
- MAIA $1.97
- Resistance Level
- KULR $2.69
- MAIA $2.44
- Average True Range (ATR)
- KULR 0.57
- MAIA 0.20
- MACD
- KULR -0.21
- MAIA 0.00
- Stochastic Oscillator
- KULR 12.77
- MAIA 8.33
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems; artificial intelligence and Cloud computing; energy storage; and 5G communication technologies.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.